biostudies-literatureVari BEuropean Union and the State of Hungary and was co-financed by the European Regional Development FundHungarian Scientific Research FundNational Research, Development and Innovation Fund of Hungary, and within the framework of the ELTE Thematic Excellence Programme 2020, National Challenges SubprogrammeHungarian Thematic Excellence ProgrammeNational Laboratories Excellence programEuropean Union′s Horizon 2020 research and innovation programHungarian Ministry for Innovation and Technology2174210https://www.ebi.ac.uk/biostudies/studies/S-EPMC9930758biostudies-literatureUnknown30(1)Chemotherapy is still a leading therapeutic approach in various tumor types that is often accompanied by a poor prognosis because of metastases. PEGylated liposomes with CREKA targeting moiety are well-known therapeutic agents, especially in highly metastatic experimental models. CREKA specifically targets tumor-associated ECM, which is present at the primary, as well as metastatic tumor sites. To better understand the function of the targeting moieties, we decided to design various liposome formulations with different amounts of targeting moiety attached to their DSPE-PEG molecules. Moreover, a new tumor-homing pentapeptide (SREKA) was designed, and a novel conjugation strategy between SREKA and DSPE-PEGs. First, the <i>in vitro</i> proliferation inhibition of drug-loaded liposomes and thDrug deliverySREKA-targeted liposomes for highly metastatic breast cancer therapy.PMC9930758NKFIH-OTKAVEKOP-2.3.3-15-2017-00020TKP2020-NKA-06TKP2021-EGA-442022-2.1.1-NL-2022-00010K1195528613162018-1.2.1-NKP-2018-00005Dokus LSolyom-Tisza ASzoboszlai NVari BMezo GTovari JGaal ARanđelovic IBorbely AVari-Mezo DVarga ZfalseSREKA-targeted liposomes for highly metastatic breast cancer therapy.Chemotherapy is still a leading therapeutic approach in various tumor types that is often accompanied by a poor prognosis because of metastases. PEGylated liposomes with CREKA targeting moiety are well-known therapeutic agents, especially in highly metastatic experimental models. CREKA specifically targets tumor-associated ECM, which is present at the primary, as well as metastatic tumor sites. To better understand the function of the targeting moieties, we decided to design various liposome formulations with different amounts of targeting moiety attached to their DSPE-PEG molecules. Moreover, a new tumor-homing pentapeptide (SREKA) was designed, and a novel conjugation strategy between SREKA and DSPE-PEGs. First, the <i>in vitro</i> proliferation inhibition of drug-loaded liposomes and th2023-01-01T00:00:00Z2023 Dec2025-04-04T11:17:27.682Z2025-04-04T11:17:27.682ZS-EPMC99307583675207510.1080/10717544.2023.2174210